A phase-1 dose escalation and expansion study of EP0031, a next-generation selective RET inhibitor (SRI), in patients with SRI-naïve or pretreated advanced RET-altered NSCLC and other tumors.
Elena Garralda(Memorial Sloan Kettering Cancer Center), Pilar Garrido(Hospital Universitario Ramón y Cajal), Javier García-Corbacho(Hospital Clínico Universitario Virgen de la Victoria), Andrew G. Gianoukakis(UCLA Medical Center), David R. Spigel(Sarah Cannon), Sarina A. Piha‐Paul(The University of Texas MD Anderson Cancer Center), Guzmán Alonso(Vall d'Hebron Hospital Universitari), Susanne M. Arnold(University of Kentucky), Daniel Morgensztern(Barnes-Jewish Hospital), Matthew H. Taylor(Providence Portland Medical Center), Sonia Serrano, Vivek Subbiah(Sarah Cannon), Susan Brook, Antoîne Italiano(Memorial Sloan Kettering Cancer Center), Geoff Fisher, Martin Förster, Matthew Krebs(Christie's), Miguel García-Pardo(Hospital Universitario Ramón y Cajal), Judy S. Wang(Sarah Cannon), Hendrik‐Tobias Arkenau(Sarah Cannon Research Institute)
Cited by 2
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k